Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.

about

Therapeutic advances in sickle cell disease in the last decade.

P2860

Q44223235-BE60A840-9DB3-4BB3-B979-EB46BCC6D7FE

P2860

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.

Item

http://www.wikidata.org/entity/Q36718353

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.

@ast

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.

@en

type

Item

label

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.

@ast

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.

@en

prefLabel

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.

@ast

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.

@en

P1476

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia

@en

P2093

Bijan Keikhaei

http://www.w3.org/2001/XMLSchema#string

Homayon Yousefi

http://www.w3.org/2001/XMLSchema#string

Mohammad Bahadoram

http://www.w3.org/2001/XMLSchema#string

P2860

Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase

Hydroxyurea therapy in 49 patients with major beta-thalassemia.

Hydroxyurea in sickle cell disease: drug review.

Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease?

Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model.

Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia.

Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.

Infection in sickle cell disease: a review.

Update on the use of hydroxyurea therapy in sickle cell disease

Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment.

P304

252-256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5539/GJHS.V8N3P252

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bijan Keikhaei

Homayon Yousefi

Mohammad Bahadoram

P577

2015-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26493428

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

4803938

http://www.w3.org/2001/XMLSchema#string

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.

about

P2860

P2860

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932